Sir,

I read with great interest the recent SASLT statement on the direct-acting antiviral agents (DAA) for the treatment of hepatitis C virus (HCV) infection that was published in this journal.\[[@ref1]\] The panel of experts stated that all DAAs listed in their table are equally efficacious for the management of HCV patients. However, some of these regimens have different sustained virological response (SVR) rates among different genotypes.

The panel of experts recommended sofosbuvir and ledipasvir in combination with ribavirin (RBV) for 12 weeks in naïve cirrhotic patients or for 24 weeks among null responder cirrhotics. This combination has been evaluated in HCV genotype (GT) 1 cirrhotic patients in ION-1 and ION-2 studies.\[[@ref2]\] Treatment-naïve or treatment-experienced patients with cirrhosis were randomly assigned to 12 or 24 weeks of sofosbuvir/ledipasvir with or without RBV. Among treatment-experienced cirrhotic patients, SVR rate after 24 weeks of therapy was higher than the SVR rate after 12 weeks of therapy (100% vs. 86%), without a clear benefit of the use of RBV. However, in a subsequent larger study (SIRIUS) in treatment-experienced cirrhotic GT1 patients,\[[@ref3]\] participants were randomized to 24 weeks of sofosbuvir/ledipasvir or 12 weeks with the addition of RBV. The SVR rates were similar in both groups. Therefore, the 12-week regimen with RBV can be used as an alternative option to 24 weeks of sofosbuvir/ledipasvir in treatment-experienced GT1 patients.

Another recommendation was sofosbuvir and simeprevir for 12 weeks in combination with RBV. In the COSMOS study, treatment-naïve or treatment-experienced cirrhotic HCV GT1 patients received this combination with or without RBV for 12 or 24 weeks.\[[@ref4]\] The SVR rate ranged from 79 to 100%, without a clear benefit of the extended therapy or the use of RBV. Therefore, RBV has not been recommended with this combination. Likewise, this combination might be very effective in managing patients with HCV GT4. However, there is a lack of data to support the use of this combination in these patients. On the other hand, the combination of sofosbuvir and RBV was evaluated among treatment-naïve or treatment-experienced cirrhotics with GT4. Patients were randomly assigned to 12 or 24 weeks of therapy. Indeed, cirrhotics benefited from prolonged therapy; the SVR rate was 67% in the group treated for 12 weeks compared to 100% in the group treated for 24 weeks. However, the SVR rate was lower in treatment-experienced cirrhotic patients: 60% in the 12-week treatment group and 67% in the 24-week treatment group.\[[@ref5]\] Also, the 12-week regimen of sofosbuvir/ledipasvir has been evaluated in GT4 patients. The SVR rate was 95% based on 21 patients (38% treatment-experienced; 40% with cirrhosis). Due to the small sample size, more studies are required to validate this combination among cirrhotic HCV GT4 patients.

Next, the panel of experts recommended paritaprevir, ritonavir, ombitasvir, dasabuvir, and RBV for 12 weeks (F3, GT4) or 24 weeks (GT4, cirrhosis). This regimen has been evaluated in treatment-naïve and treatment-experienced non-cirrhotics with HCV GT4.\[[@ref6]\] Therefore, future studies are required to assess the safety and efficacy of this regimen among cirrhotics with GT4.

The expert panel also recommended daclatasvir and sofosbuvir in combination with RBV for 12 weeks for treatment-naïve or for 24 weeks for treatment-experienced cirrhotics. This regimen has been evaluated in treatment-naïve and treatment-experienced HCV GT1 patients.\[[@ref7]\] Cirrhotic patients were excluded from the study. The SVR rate was 98% in both groups, without clear benefit of the use of RBV.

In the ALLY-3 study, treatment-naïve or treatment-experienced patients with HCV GT3 received 12-week regimen of daclatasvir and sofosbuvir, and 19 (19%) patients in the treatment-naïve group and 13 (25%) patients in the treatment-experienced group had cirrhosis. The SVR rate was higher in non-cirrhotics compared to cirrhotics (96% vs 63%). In this study, the addition of RBV or the extension of duration of therapy was not explored. Therefore, a larger sample size with a longer duration of treatment is required in cirrhotic GT3 patients.

Finally, the expert panel failed to mention that sofosbuvir and RBV is a therapeutic option, especially in prioritized patients with HCV GT2. In the VALENCE study, treatment-naïve or treatment-experienced GT2 patients received 12-week regimen of sofosbuvir and RBV. The SVR rate ranged from 97 to 100% in the treatment-naïve patients. However, the SVR rate was lower in treatment-experienced cirrhotics (88%).\[[@ref8]\]

In conclusion, the new DDAs are very effective and well tolerable even in patients with advanced liver disease. Multiple IFN-free regimens are available, including regimens for difficult-to-treat patients, with an excellent SVR rate. However, access to these therapies is quite limited by cost, although market competition will eventually drive down the costs.
